Company Overview and News

 
Rimfire Pacific Mining chairman adds to stake

2018-09-06 proactiveinvestors.com.au
Rimfire Pacific Mining N L (ASX:RIM) non-executive chairman Ian McCubbing has upped his stake in the company by more than 1 million shares in an on-market acquisition valued at $11,450.34.
SWK RIM SWCKF KAS KASBF AEV

 
Swick introduces Orexplore mineral scanning tech at gold project

2018-07-03 australianmining.com.au
Swick Mining Services has secured the first commercial agreement for the company’s Orexplore mineral scanning technology.
SWK SWCKF

 
Swick signs first commercial technology agreement

2018-07-03 businessnews.com.au
Swick Mining Services has announced the first commercial agreement for use of its Orexplore mineral scanning technology, which has been developed over the past seven years.
SWK SWCKF

3
Swick wins $80m contract extensions

2018-06-29 businessnews.com.au
Swick Mining Services has announced two contract extensions worth about $80 million, including a renewal at Northern Star Resources’ Jundee gold mine near Wiluna.
SWK SWCKF NST NHRNY NESRF

3
Swick Mining Services grows order book with contracts at Jundee and Renison

2018-06-29 proactiveinvestors.com.au
Swick Mining Services Ltd (ASX:SWK) has been chosen as contractor or preferred contractor across two projects, which will double the company’s order book to around $160 million.
SWK MLX SWCKF NST NHRNY NESRF MLXEF

3
Swick adds $80m of contract extensions as drill rig demand surges

2018-06-29 australianmining.com.au
Swick Mining Services has experienced increasing demand for its drill rigs, reflected by a pair of contract renewals that bolster its order book to $160 million.
SWK SWCKF NST NHRNY NESRF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:SWK / SWICK MINING SERVICES LTD on message board site Silicon Investor.

SWKS - Skyworks Solutions, Inc (was AHAA) SWKS - Skyworks Solutions, Inc (was AHAA) SWKS - Skyworks Solutions, Inc (was AHAA) Stanley Works (SWK) Stanley Works (SWK) Stanley Works (SWK)
Skyworks (SWKS) Skyworks (SWKS) Skyworks (SWKS) SWKS - Skyworks Solutions, Inc. SWKS - Skyworks Solutions, Inc. SWKS - Skyworks Solutions, Inc.